## David R Compton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2235986/publications.pdf

Version: 2024-02-01

34 papers

4,242 citations

20 h-index 395702 33 g-index

34 all docs

34 docs citations

times ranked

34

2945 citing authors

#	Article	IF	CITATIONS
1	Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology, 1995, 50, 83-90.	4.4	2,561
2	Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacology Biochemistry and Behavior, 1991, 40, 471-478.	2.9	384
3	Design, Synthesis and Pharmacology of Cannabimimetic Indoles. Bioorganic and Medicinal Chemistry Letters, 1994, 4, 563-566.	2.2	241
4	Synthesis and Pharmacology of a Very Potent Cannabinoid Lacking a Phenolic Hydroxyl with High Affinity for the CB2 Receptor. Journal of Medicinal Chemistry, 1996, 39, 3875-3877.	6.4	149
5	Stereochemical effects of 11-OH-Δ8-THC-dimethylheptyl in mice and dogs. Pharmacology Biochemistry and Behavior, 1989, 32, 661-666.	2.9	108
6	1-Alkyl-3-(1-naphthoyl)pyrroles: A new class of cannabinoid. Tetrahedron Letters, 1995, 36, 1401-1404.	1.4	107
7	Pharmacological and behavioral evaluation of alkylated anandamide analogs. Life Sciences, 1995, 56, 2041-2048.	4.3	66
8	Synthesis and Pharmacological Comparison of Dimethylheptyl and Pentyl Analogs of Anandamide. Journal of Medicinal Chemistry, 1997, 40, 3626-3634.	6.4	63
9	Canabis Dependence and Tolerance Production. Advances in Alcohol & Substance Abuse, 1990, 9, 129-147.	0.5	59
10	Proarrhythmic mechanisms of the common anti-diarrheal medication loperamide: revelations from the opioid abuse epidemic. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 1133-1137.	3.0	55
11	Cannabinoid receptors in developing rats: detection of mRNA and receptor binding. Drug and Alcohol Dependence, 1994, 36, 27-31.	3.2	53
12	Agonist-antagonist characterization of 6′-cyanohex-2′-yne-Δ8-tetrahydrocannabinol in two isolated tissue preparations. European Journal of Pharmacology, 1996, 315, 195-201.	3.5	41
13	5'-AzidoDELTA.8-THC: a novel photoaffinity label for the cannabinoid receptor. Journal of Medicinal Chemistry, 1992, 35, 3076-3079.	6.4	40
14	Pharmacological evaluation of iodo and nitro analogs of î"8-THC and î"9-THC. Pharmacology Biochemistry and Behavior, 1993, 46, 295-301.	2.9	36
15	Ontogeny of mu opioid agonist anti-nociception in postnatal rats. Developmental Brain Research, 1998, 105, 269-276.	1.7	33
16	Synthesis and pharmacological evaluation of ether and related analogs of .DELTA.8-, .DELTA.9-, and .DELTA.9,11-tetrahydrocannabinol. Journal of Medicinal Chemistry, 1991, 34, 3310-3316.	6.4	26
17	Synthesis and Pharmacological Properties of 11-Hydroxy-3-(1',1'-dimethylheptyl)hexahydrocannabinol: A High Affinity Cannabinoid Agonist. Journal of Medicinal Chemistry, 1994, 37, 2619-2622.	6.4	26
18	Side chain methyl analogues of Δ8-THC. Tetrahedron, 1997, 53, 1557-1576.	1.9	24

#	Article	IF	CITATIONS
19	Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogs of 10-substituted cannabidiol and 11- or 12-substituted .DELTA.8-tetrahydrocannabinol. Journal of Medicinal Chemistry, 1990, 33, 1437-1443.	6.4	23
20	A novel class of potent tetrahydrocannabinols (THCS): 2′-YNE-Δ8- and Δ9-THCS. Life Sciences, 1995, 56, 2013-2020.	4.3	21
21	Importance of the C-1 Substituent in Classical Cannabinoids to CB2Receptor Selectivity: Synthesis and Characterization of a Series of O,2-Propano-Δ8-tetrahydrocannabinol Analogs. Journal of Medicinal Chemistry, 1997, 40, 3312-3318.	6.4	17
22	Gene therapy in the putamen for curing AADC deficiency and Parkinson's disease. EMBO Molecular Medicine, 2021, 13, e14712.	6.9	17
23	Stereoselective synthesis of the epimeric î"7-tetrahydrocannabinols. Tetrahedron, 1995, 51, 1017-1032.	1.9	15
24	Pharmacological evaluation of water soluble cannabinoids and related analogs. Life Sciences, 1990, 46, 1575-1585.	4.3	14
25	Striatal synaptosomal dopamine synthesis: Evidence against direct regulation by an autoreceptor mechanism. European Journal of Pharmacology, 1985, 110, 157-162.	3.5	10
26	Evaluation of Agonist-antagonist Properties of Nitrogen Mustard and Cyano Derivatives of î" 8 -Tetrahydrocannabinol. Neuropharmacology, 1996, 35, 1793-1804.	4.1	10
27	Nonclinical Studies that Support Viral Vector-Delivered Gene Therapies: An EFPIA Gene Therapy Working Group Perspective. Molecular Therapy - Methods and Clinical Development, 2020, 19, 89-98.	4.1	9
28	Comparative effects of interferon alphaâ€2b and pegylated interferon alphaâ€2b on menstrual cycles and ovarian hormones in cynomolgus monkeys. Birth Defects Research Part B: Developmental and Reproductive Toxicology, 2009, 86, 29-39.	1.4	8
29	(+)- and (-)-N-allylnormetazocine binding sites in mouse brain: In vitro and in vivo characterization and regional distribution Life Sciences, 1987, 40, 2195-2206.	4.3	7
30	Modification of phencyclidine intoxification and biodisposition by charcoal and other treatments. Pharmacology Biochemistry and Behavior, 1988, 30, 371-377.	2.9	6
31	Synthesis and pharmacological evaluation of mercapto and thioacetyl analogues of cannabidiol and Δ8-tetrahydrocannabinol. European Journal of Medicinal Chemistry, 1989, 24, 293-297.	5.5	6
32	Pharmacological characterization of BNMPA ( $\hat{l}_{\pm}$ -benzyl-N-methylphenethylamine), an impurity of illicit methamphetamine synthesis. European Journal of Pharmacology, 1996, 311, 133-139.	3.5	3
33	Neurochemistry of Abuse Liability Assessment and Primary Behavioral Correlates., 2015,, 9-48.		2
34	Abuse liability assessment for biologic drugs – All molecules are not created equal. Regulatory Toxicology and Pharmacology, 2018, 92, 165-172.	2.7	2